Aeglea BioTherapeutics Investor Presentation Deck
SPY001 potency & selectivity matches vedolizumab
SPY001 & VEDOLIZUMAB EPITOPE
SPY001 and
vedolizumab
bind the same
epitope
a4 Subunit
POTENT & SELECTIVE BINDING TO a437
Antibody
a437¹
a4³1 aEB7
K₂ <1 nM
NB²
NB²
SPY001
B7 Subunit
Source: Data on file.
Vedolizumab
K₂ <1 nM
NB²
1Dissociation constant (K) measured by surface plasmon resonance (SPR)
2NB = no binding by a particular antibody to a test molecule
SPYRE
NB²
POTENT AND SELECTIVE INHIBITION OF CELLULAR ADHESION
SPY001 and vedolizumab potently inhibit
MADCAM-1-mediated (gut) cellular adhesion
%Inhibition of Total Adhesion
(Integrin-mediated Adhesion by MADCAM-1)
70
60-
50-
40-
30-
20-
10-
SPY001 (IC50 = 86 PM)
● Vedolizumab (IC50 = 83 PM)
●
0.01
0.1
1
mAb Concentration (nM)
10
No inhibition of unwanted VCAM-1-
mediated (CNS) cellular adhesion
%Inhibition of Total Adhesion
(Integrin-mediated Adhesion by VCAM-1)
70
60
50
40-
30
20-
10
0
-10
●
SPY001
Vedolizumab
Natalizumab (a431)
0.001
HO
T
0.01
0.1
1
mAb Concentration (nM)
10
100
10View entire presentation